APA (7th ed.) Citation

A, B., & GPC, D. (2024). A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations. Frontiers in molecular biosciences, 10, 1306046. https://doi.org/10.3389/fmolb.2023.1306046

Chicago Style (17th ed.) Citation

A, Balasundaram, and Doss GPC. "A Computational Examination of the Therapeutic Advantages of Fourth-generation ALK Inhibitors TPX-0131 and Repotrectinib over Third-generation Lorlatinib for NSCLC with ALK F1174C/L/V Mutations." Frontiers in Molecular Biosciences 10 (2024): 1306046. https://doi.org/10.3389/fmolb.2023.1306046.

MLA (9th ed.) Citation

A, Balasundaram, and Doss GPC. "A Computational Examination of the Therapeutic Advantages of Fourth-generation ALK Inhibitors TPX-0131 and Repotrectinib over Third-generation Lorlatinib for NSCLC with ALK F1174C/L/V Mutations." Frontiers in Molecular Biosciences, vol. 10, 2024, p. 1306046, https://doi.org/10.3389/fmolb.2023.1306046.